. However, N-Myc protein (the product of the MYCN oncogene) is stabilized in neuroblastoma by the protein kinase Aurora-A in a manner that is sensitive to certain Aurora-A-selective inhibitors. Here we identify a direct interaction between the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds SCF FbxW7 . We determined the crystal structure of the complex between Aurora-A and this region of N-Myc to 1.72-Å resolution. The structure indicates that the conformation of Aurora-A induced by compounds such as alisertib and CD532 is not compatible with the binding of N-Myc, explaining the activity of these compounds in neuroblastoma cells and providing a rational basis for the design of cancer therapeutics optimized for destabilization of the complex. We also propose a model for the stabilization mechanism in which binding to Aurora-A alters how N-Myc interacts with SCF FbxW7 to disfavor the generation of Lys48-linked polyubiquitin chains. structural biology | Aurora-A kinase | protein-protein interaction | Myc | neuroblastoma M yc proteins are transcription factors that markedly alter gene expression through both activation and repression of transcription (1, 2) . Three Myc protein family members can be aberrantly expressed in human cancers. Cellular Myc (c-Myc) was first discovered as the cellular homolog of the viral Myc (v-Myc) oncoprotein and is frequently deregulated in a wide range of human cancers (3) (4) (5) . N-Myc and L-Myc were subsequently identified as the products of amplified genes MYCN in neuroblastoma and MYCL in small cell lung cancer, respectively (6) (7) (8) . Inhibition of Myc is a validated therapeutic strategy, but efforts to develop clinical compounds that target Myc proteins directly have failed (9) . c-Myc, N-Myc, and L-Myc have regions of sequence homology that mediate interactions with critical partner proteins such as Max, WDR5, TRRAP, PAF1C, and the protein kinase Aurora-A (10) . The most C-terminal of these regions forms an essential DNA-binding domain through formation of a basic helix-loophelix leucine zipper domain in complex with Max (9, 11) . Other conserved sequence motifs called "Myc boxes" (MB0-IV) serve as docking sites for protein-protein interactions (10, 12, 13) . The Myc transactivation domain (TAD) spans the N-terminal conserved motifs MB0, MBI, and MBII. The TAD of c-Myc is intrinsically disordered, as reported by circular dichroism and NMR spectroscopy, but there are transient secondary structure elements that in some cases become stable in complex with binding partners (12, 14, 15) .
The stability of Myc proteins is regulated by phosphorylation within MBI, which targets the protein for ubiquitinylation and proteolysis. For example, N-Myc is first phosphorylated on Ser62 by Cdk1/cyclin B and is then phosphorylated on Thr58 by Gsk3β (16) . Dephosphorylation of Ser62 by PP2A directs the activity of the E3 ubiquitin ligase SCF FbxW7 to modify N-Myc with K48-linked ubiquitin chains (17, 18) . In neuroblastoma cells, the Ser/ Thr protein kinase Aurora-A blocks this process, resulting in an excess of N-Myc protein (19) . Aurora-A binds to the N-Myc/ SCF FbxW7 complex and reduces the proportion of K48 linkages in the polyubiquitin chains. Catalytic activity of Aurora-A is not required for N-Myc stabilization, and the underlying mechanism is unclear. Some Aurora-A inhibitors such as MLN8237/alisertib and CD532 can destabilize N-Myc by disrupting the complex, whereas other Aurora-A inhibitors have no effect (19, 20) . The current hypothesis is that the destabilizing inhibitors alter the conformation of Aurora-A in ways that disrupt the complex, but inhibitors that compete with ATP without causing a conformational change leave the complex intact (20) (21) (22) .
We set out to investigate the structural basis of Aurora-A stabilization of N-Myc and the effect of Aurora-A inhibitors on the complex. Here we show that the catalytic domain of Aurora-A interacts directly with N-Myc through binding sites that flank either side of MBI. We present a crystal structure of the complex between Aurora-A and a fragment of N-Myc corresponding to the region immediately C-terminal to MBI which reveals Significance Elevated levels of N-Myc protein (the product of the MYCN oncogene) drive cancers such as neuroblastoma. Accumulation of N-Myc in these cancer cells depends upon the formation of a complex with the protein kinase Aurora-A in which the N-Myc is not properly degraded. We mapped the region of N-Myc that interacts with Aurora-A and determined the molecular structure of the complex. Because this region also interacts with cellular machinery that targets N-Myc for degradation, we sought to understand the mechanism by which N-Myc stabilizes Aurora-A. The structure explains how compounds that induce distorted conformations of Aurora-A are able to disrupt the interaction with N-Myc. This understanding may provide a basis for designing better compounds that work in this way for the treatment of neuroblastoma.
Aurora-A in a fully active conformation that is incompatible with inhibitors of Aurora-A that disrupt the complex. Biochemical studies show an interaction between SCF FbxW7 and the same region of N-Myc, and we propose that the way in which Aurora-A interferes with this interaction changes N-Myc ubiquitination to promote stability.
Results and Discussion
Structural Basis of the Interaction Between N-Myc and Aurora-A. To show that Aurora-A and N-Myc interact directly, we carried out a coprecipitation experiment using a GST-Aurora-A kinase domain fusion protein incubated with a range of purified fragments from the N-Myc TAD (Fig. S1A ). This method identified residues 28-89 of N-Myc as the minimal Aurora-A-interaction region (AIR), which spans MB0 through MBI but does not include MBII or beyond (Fig. 1A) . The binding affinity of Aurora-A for the AIR was quantified as 2.9 ± 0.5 μM by ELISA (Fig. S1B ) and as 1.0 ± 0.3 μM by competition AlphaScreen assay (Fig. 1B) . The presence of a Trp residue toward the C terminus of this N-Myc fragment was striking, and mutation of Trp88 to Ala abrogated the interaction in the context of the entire N-Myc TAD fragment (residues 1-137) in a precipitation experiment with GST-tagged Aurora-A catalytic domain (residues 122-403); the TAD of N-Myc did not interact with GST alone. Taken together, these results indicate that the interaction is specific (Fig. S1C) .
To elucidate the structural basis of the Aurora-A/N-Myc interaction, we crystallized a complex between the Aurora-A kinase domain with surface Cys mutated to enhance stability (Aurora-A C290A/C393A
) and a synthetic N-Myc peptide corresponding to residues 28-89. The crystals yielded diffraction data to 1.72-Å resolution, and we solved the structure by molecular replacement using an existing structure of Aurora-A C290A/C393A (Table S1 and Fig. S1D ). Residues 28-60 of N-Myc are not observed in the structure, whereas residues 61-89 are associated with the cleft between the N-and C-lobes of the Aurora-A kinase domain formed by the αB/αC helices, the activation loop, and the αG helix (Fig. 1C) . N-Myc residues 76-89 form an α-helix, which packs onto the C-lobe of Aurora-A at a surface formed by Tyr334, Gln335, and Tyr338 with its N terminus pointing toward the substrate-binding region. Both ends of the α-helix are capped by Trp residues (Trp77 and Trp88), whose side chains pack against the surface of Aurora-A. Key intermolecular interactions include a salt bridge between Glu73 of N-Myc and Lys143 from the Gly-rich loop on the N-lobe of Aurora-A, an additional interaction between Gln335 of Aurora-A and Trp88 of N-Myc, and the insertion of the Trp77 side chain of N-Myc into the hydrophobic P+1 pocket in the activation loop region of Aurora-A (Fig. 1D) . A pair of prolines (Pro74 and Pro75) breaks the α-helix at its N terminus and directs the chain toward the Aurora-A N-lobe. Residues 69-71 are hydrogen-bonded into a turn, and residues 61-67 are bound into a groove between the N-lobe and the surface formed by the activation loop.
The region of N-Myc observed in the crystal structure starts at the C terminus of MBI and is not conserved in c-Myc (Fig. S2A) . Our initial mapping suggested that this region was insufficient for binding, so we used a more sensitive assay based on changes in fluorescence polarization (FP) using synthetic peptides of N-Myc to confirm that residues 61-89 of N-Myc bind Aurora-A independently, with a measured K d of 12 μM (Fig. S2B) . N-Myc peptides with E73K or W77A mutations reduced binding to Aurora-A, consistent with their observed contributions to the interface in the crystal structure (Fig. S2B) . Similarly, the contributions of Aurora-A Y334 and Q335 to the interaction were confirmed.
The section of the AIR that was not resolved in the crystal structure, residues 28-60 of N-Myc, includes the MB0 and MBI regions and is conserved in c-Myc (Fig. S2A ). Having shown that the C-terminal part of the AIR was able to bind Aurora-A independently, we looked for other subfragments that might contribute to binding with a sensitive pull-down assay using peptides spanning the region, under less stringent conditions than the first set of pull-downs used for mapping the interaction (Fig. S2C ). In addition to residues 61-89, a region corresponding to MB0 was also capable of independent interaction with Aurora-A. Using the FP assay, we confirmed that a peptide spanning residues 19-47 of N-Myc, including MB0, binds independently to Aurora-A (Fig. S2D ). The presence of conserved aromatic residues in this region is striking (F28, Y29, F35, Y36), and these residues were shown to contribute to the interaction with Aurora-A (Fig. S2D) . In contrast to the established roles of the regions flanking it, MBI itself does not appear to contribute to the interaction with Aurora-A, because a peptide corresponding to residues 44-64 showed no binding in the peptide coprecipitation assay ( the N-Myc 28-89 peptide (Fig. S2E) . We postulate that the flanking regions on either side of MBI form specific interactions with Aurora-A, linked by the MBI region itself, which interacts in a phosphorylation-dependent manner with FbxW7 but makes no critical interactions with Aurora-A.
N-Myc Activates Aurora-A and Competes with TPX2, the Targeting Protein for Xklp2. When bound to N-Myc, Aurora-A is in a fully active conformation similar to that observed for the Aurora-A/ TPX2 complex ( Fig. 2A) (23) . The microtubule-associated protein-targeting protein for Xklp2 (TPX2) binds to Aurora-A through its first 43 residues: amino acids 7-21 at a site on the N-lobe and amino acids 30-43 at a site between the two lobes. The conformation adopted by Aurora-A when bound to TPX2 is incompatible with the interaction of N-Myc residues 61-67 (Fig.  2B ). There is a clear steric clash, because Leu61 of N-Myc binds to the same pocket on the Aurora-A surface as Trp34/Phe35 of TPX2. To accommodate the marked increase in size in going from the single Leu side chain of N-Myc to the two bulky side chains of TPX2, the side chain of Aurora-A residue His187 rotates out of the pocket in the TPX2-bound conformation. Side chains on the αC-helix of Aurora-A such as His176 and Arg179 are also observed in different positions, suggesting that the N-terminal stretch of TPX2 (Tyr8/Tyr10) that binds on one side of the αC-helix is incompatible with binding of N-Myc to the other side of the αC-helix. Consistent with this structural analysis, the first 43 amino acids of TPX2 and the AIR of N-Myc compete for binding to Aurora-A (Fig. 2C) , and they also have comparable affinities, because K d values of 2-3 μM were measured for both proteins in ELISAs using immobilized Aurora-A (Fig. S1B) . Competition with TPX2 was observed for the individual regions of the AIR both N-and C-terminal to MB1 (Fig. 2C) , suggesting that the binding site for MB0 on Aurora-A also overlaps with that of TPX2. The AIR of N-Myc, like TPX2, initially activates unphosphorylated Aurora-A, so there is also functional overlap between these two Aurora-A-binding proteins (Fig. 2D and Fig.  S3 ). The crystal structure reported here does not reveal the mechanism by which N-Myc activates Aurora-A, because residues 61-89 of N-Myc were not sufficient to activate Aurora-A, and we used Aurora-A prephosphorylated on Thr288 to form the complex. However, it is clear that N-Myc, like TPX2, is able to trigger Aurora-A activation through protein-protein interactions, and the result is a stabilized conformation of Aurora-A in which the activation loop forms a platform for the binding of N-Myc residues 61-89 (Fig. 2E) . Furthermore, as shown in (20, 21) . In contrast, most Aurora-A inhibitors, such as CCT137690, do not substantially affect the structure of the protein (24) . There is no available crystal structure of MLN8237 bound to Aurora-A, but the chemical structures of MLN8054 and MLN8237 are almost identical, and it is likely that MLN8237 induces a similar conformation in Aurora-A. We compared the structures of Aurora-A in complex with N-Myc, MLN8054, CD532, and CCT137690 (Fig. 3A) . Aurora-A grips N-Myc through interactions involving both the N-and C-lobes of the kinase (colored orange in Fig. 3A) . Binding of CCT137690 does not affect the relative orientation of the two kinase lobes. The activation loop of Aurora-A is disordered in the Aurora-A/CCT137690 structure because it is neither phosphorylated nor stabilized by a protein such as TPX2 or N-Myc, and there is no obvious mechanism by which CCT137690 could affect the activation loop. However, when Aurora-A is bound to MLN8054 or CD532, the surfaces that form the binding site for residues 61-89 of N-Myc are moved apart through motions that twist the two kinase lobes relative to one another and displace the activation loop (Fig. 3B) . The rearrangement of this binding site provides a possible mechanism by which compounds such as MLN8054 disrupt the Aurora-A/N-Myc complex by acting as a wedge that forces the kinase into an inactive conformation. The key differences between CCT137690 and MLN8054 are that only the latter makes a specific contact with the displaced activation loop; although both compounds contact both the hinge and the Gly-rich loop, the wedge effect is a function of the 3D shape of MLN8054 in contrast to the flatter scaffold of CCT137690.
Consistent with the structural analysis, MLN8054 but not CCT137690 disrupted the direct interaction of the catalytic domain of Aurora-A with its binding sites within the AIR (Fig. 3C) . Indeed, Aurora-A bound to MLN8054 displayed two-to threefold reduced affinity for both of the binding sites within the AIR of N-Myc compared with Aurora-A alone (Fig. S4) . Next, we used proximity ligation assays to quantify complex formation between endogenous N-Myc and Aurora-A proteins in a neuroblastoma cell line (Fig. 3 D and E) and observed significantly fewer interactions in cells treated with MLN8054 or MLN8237 than in untreated cells, whereas the number of interactions was unaffected by treatment with CCT137690.
A Model for the Regulation of N-Myc Ubiquitination by Aurora-A. In this study, we showed that Aurora-A binds N-Myc irrespective of its phosphorylation state and interacts with regions of N-Myc that flank MBI. The binding interaction between the Aurora-A catalytic domain and N-Myc residues 61-89 that we have resolved is immediately adjacent to the phospho-degron motif centered on Thr58. Phosphorylation of this motif is required for recognition of N-Myc by SCF FbxW7 . Thus, binding of Aurora-A might affect the interaction of N-Myc with SCF FbxW7 . Using purified proteins, we discovered that SCF FbxW7 , like Aurora-A, interacts with N-Myc irrespective of the phosphorylation state of Thr58/Ser62 (Fig. 4A) . Binding of SCF FbxW7 to N-Myc that is phosphorylated on Thr58/Ser62 was not affected by Aurora-A, as is consistent with nonoverlapping binding sites on N-Myc. In contrast, Aurora-A competed with SCF FbxW7 for binding to unphosphorylated N-Myc. This observation suggested that the interaction of SCF FbxW7 with unphosphorylated N-Myc might depend on a binding site that overlaps with one or both of the Aurora-A binding sites that flank MBI. Binding of SCF FbxW7 was mapped to residues 61-89 of N-Myc; binding to residues 48-89 of N-Myc was also observed, but an unphosphorylated MBI peptide (residues 44-64) did not bind (Fig. 4B) . Aurora-A efficiently competed with SCF FbxW7 for binding to residues 48-89 of N-Myc in a dose-dependent manner, whereas a control protein bovine serum albumin (BSA) did not compete (Fig. 4C) . Taken together, these results show that there is competition between Aurora-A and SCF FbxW7 for binding to residues 61-89 of N-Myc, the region bound to Aurora-A in the crystal structure.
These observations suggest a working model by which Aurora-A could stabilize N-Myc by altering its interaction with SCF FbxW7 ; we put forward this model as a basis for further investigation (Fig. 4D) . Recruitment of N-Myc to SCF FbxW7 is driven by the well-characterized interaction between the phospho-degron and FbxW7 that is regulated by phosphorylation of Thr58. However, a second interaction is also formed between N-Myc residues 61-89 and an unknown site on SCF FbxW7 . Aurora-A binds to N-Myc at sites that flank the phospho-degron, disrupting the interaction between residues 61-89 of N-Myc and SCF FbxW7 but not the phospho-degron region; thus a complex of Aurora-A, N-Myc, and SCF FbxW7 is formed. We postulate that the interaction between N-Myc residues 61-89 and SCF FbxW7 is important for efficient polyubiquitination of N-Myc and that disruption of this interaction by Aurora-A reduces the formation of Lys48-linked chains on N-Myc, as previously reported (19) .
The dysregulation of Myc proteins is a feature of several cancers that are refractory to treatment, and targeting Myc is a validated therapeutic strategy (9, (25) (26) (27) . Unfortunately, there are currently no drug-like molecules that target Myc directly. Myc family proteins are intrinsically disordered proteins that dynamically adopt many conformations and therefore lack "druggable" pockets. This property has frustrated attempts to develop a drug-like molecule that directly targets the interaction of Myc with its binding partners. Here we have characterized the complex with Aurora-A in which N-Myc is trapped in an ordered conformation. The interaction can be disrupted by targeting the ATP-binding site of Aurora-A to induce a conformation that is incompatible with the binding of N-Myc, and early clinical trial data suggest these compounds may provide patient benefit when combined with chemotherapy (20, 22, 28) . However, this approach also would target the main function of Aurora-A in the proper assembly and the function of the mitotic spindle, and it is too early to know whether the potential benefit of this in targeting dividing cancer cells offsets the accompanying damage to normal tissue. Alternatively, it may be possible to inhibit the protein-protein interaction directly by targeting the interface. The structure of the Aurora-A/N-Myc complex provides a rational basis for the development of inhibitors that destabilize N-Myc and molecular coordinates of the interface that will facilitate structure-guided approaches to target the binding sites for ATP or N-Myc on Aurora-A.
Materials and Methods
Crystallography. Aurora-A 122-403 containing the mutations C290A and C393A was expressed and purified as described previously (29) and was gelfiltrated into 20 mM Tris (pH 7.5), 200 mM NaCl, 5 mM MgCl 2 , 5 mM β-mercaptoethanol, and 10% (vol/vol) glycerol. An N-biotinyl peptide corresponding to residues 28-89 of N-Myc and carrying a phosphothreonine at position 58 (Peptide Synthetics) was dissolved to 10 mM in DMSO. A mixture containing 300-μM Aurora-A, 5 mM adenosine diphosphate, and 500-μM N-Myc peptide [with a final DMSO concentration of 5% (vol/vol)] was incubated on ice for 1 h and then mixed 1:1 with reservoir solution [100 mM Bicine (pH 9.0), 20% (wt/vol) PEG 6000]. Crystals were obtained by vapor diffusion at 18°C within a few days and were frozen in reservoir solution supplemented with 25% (vol/vol) ethylene glycol. Diffraction data were collected from a single crystal at Diamond I03 and processed with xia2 (30) ( Table S1 ). The structure of the Aurora-A/N-Myc complex was solved by p T 5 8 / p S 6 2 n o p h o s . Iterative modeling and refinement were carried out using Coot (32) and phenix.refine (33) . Structure validation was carried out using MolProbity (34) . Crystallographic data, refinement statistics, and details of structure validation analysis are summarized in Table S1 . Structure figures were prepared using PyMOL (www.pymol.org).
Coprecipitation Assay. For in vitro peptide coprecipitation assays, 40 μL of Strep-Tactin Sepharose beads (IBA) were incubated with 900 μL of 10-μM N-biotinyl N-Myc peptides for 1 h and then were washed three times with pull-down buffer [50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl 2 , 5 mM β-mercaptoethanol, 0.02% Tween-20]. The beads were then incubated with 900 μL of a solution containing analyte proteins, competing proteins, or compounds as required for 2 h at 4°C and were washed three times with 900 μL pull-down buffer. Finally, the beads were eluted by boiling with 80 μL SDS-loading buffer, and the eluted proteins were analyzed by SDS/PAGE. Aurora-A 122-403 was used at a final concentration of 12 μM. SCF FbxW7 incorporating GST-tagged FbxW7 (Millipore) was used at a final concentration of 5.5 ng/μL and was visualized in precipitates by Western blotting using an anti-GST antibody (GE Healthcare).
Competition AlphaScreen Assay. Biotinyl Avi-tagged Aurora-A 122-403 was produced as described previously (35) . Appropriate concentrations of biotinyl Aurora-A 122-403 and 3xFlag-N-Myc 28-89 for use in competition experiments were determined in preliminary cross-titration experiments over a range of 0-300 nM. The assay buffer was 50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM MgCl 2 , 5 mM β-mercaptoethanol, 0.02% Tween-20, and 0.1% BSA. For competition assays, 10 nM biotinyl Aurora-A 122-403, 0.3 nM 3xFlag-N-Myc 28-89, and 0-160-μM Aurora-A 122-403 were mixed together and incubated at RT for 1 h in white, opaque 96-well half-area plates. Streptavidin donor beads (20 μg/mL) and anti-Flag acceptor beads (PerkinElmer) were added simultaneously to each reaction under subdued lighting conditions, and the plate was incubated for a further 90 min. The signal from each reaction was read using an EnVision multilabel plate-reader (PerkinElmer). Data points represent the mean of three experiments; error bars indicate SD. Data were analyzed using GraphPad Prism 6, and the dependence of the AlphaScreen signal on the concentration of competing Aurora-A 122-403 was fitted by nonlinear regression to a one-site logIC 50 equation in which, under the selected reaction conditions, the IC 50 value approximates the K d . Results are reported as K d ± SE.
In Situ Proximity Ligation Assay. Kelly cells were cultured in RPMI 1640 supplemented with heat-inactivated FBS. Compounds (as indicated) at 500 nM were added 4 h before fixation. Cells were fixed with 4% (vol/vol) paraformaldehyde for 30 min and permeabilized with PBS containing 0.2% Triton X-100 for a further 30 min. Cells were incubated with Duolink In situ blocking solution (Olink Bioscience) for 1 h and then with antibodies against Aurora-A (GeneTex) and N-Myc (Calbiochem) diluted into the same buffer for an additional hour. In situ proximity ligation assays were carried out using the Duolink kit (Olink Bioscience) according to the manufacturer's instructions. Images were collected and analyzed using a Humphrey 730 field analyzer system (Zeiss). The average number of interactions detected per cell was calculated, and results are reported as the mean of three independent experiments ± SD.
Kinase Assay. [
32 P]ATP kinase assays were performed as described (36) with modifications as follows. Measurement of Aurora-A activity was carried out using reactions containing 0.625-μM unphosphorylated Aurora-A catalytic domain, 40-μM myelin basic protein (Sigma), and 0-50-μM N-Myc 28-89, N-Myc 61-89, or TPX2 1-43 peptides. Reactions were incubated at 21°C for 45 min, and total incorporation of 32 P radioisotope into Aurora-A, N-Myc 28-89, and myelin basic protein was then measured by scintillation counting.
Results are reported as the mean of two independent experiments ± SE.
